Evolent Health Inc Stock Price, News & Analysis

Evolent Health has reported significant success in reducing the use of low-value oncology treatment regimens by over 20% through their provider education and engagement campaign. The program, detailed in the Journal of Clinical Pathways, focuses on identifying and decreasing the use of treatments that may have lower survival rates, more severe side effects, or excessive costs without additional clinical benefits.

The initiative spans therapies across 10 common cancer types, representing about 1% of all requests. In one striking example, a low-value lung cancer regimen was found to be approximately 70 times more expensive ($40,000 more per quarter) than a preferred alternative, without supporting evidence for better clinical outcomes.

From February through May 2024, the program achieved a 20.1% reduction in low-value regimen usage compared to the same period in 2023, with provider requests for such regimens dropping by 15.5%. The success was attributed to a comprehensive approach combining provider education, technology-enabled clinical decision support, and performance incentives.

Evolent Health (NYSE: EVH) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, followed by a conference call at 5 p.m. ET. Shareholders can access the live broadcast through Evolent's investor relations website.

Analysts can participate in the Q&A session by dialing 855.940.9467 (412.317.6034 for international callers). The company's management team will also attend several upcoming investor conferences, including:

• Needham 20th Annual Technology, Media and Consumer Conference (Virtual) - May 12, 2025
• RBC Global Health Care Conference in New York - May 21, 2025
• William Blair 45th Annual Growth Stock Conference in Chicago - June 3, 2025
• Citizens JMP Medical Devices and Healthcare Services Forum in Boston - June 17, 2025

Define Ventures, a major early-stage health tech venture capital firm, has appointed Carolyn Magill as venture partner. Magill brings 25 years of experience in healthcare, having served as CEO of Aetion and Remedy Partners, and held executive positions at Evolent Health and UnitedHealth Group.

Magill joins existing venture partners Bruce Broussard (former Humana CEO) and Frank Williams (Evolent Health co-founder) to support Define's portfolio companies. The firm, managing $800 million in assets, invests in seed to series B stage companies and has backed notable ventures like Hims & Hers.

Her expertise spans payer, provider, and pharmaceutical sectors, with particular focus on data and AI applications. At Aetion, she led a platform transforming real-world data into regulatory-grade evidence, while at Remedy Partners she oversaw bundled payments software and services.

Evolent Health (EVH) reported Q4 2024 revenue of $646.5M and full-year revenue of $2,554.7M, representing growth of 16.3% and 30.1% respectively over 2023. The company posted a Q4 net loss of $30.6M and full-year net loss of $93.5M.

Key achievements include signing contract amendments expected to yield $115M annual improvement for 2025 vs Q4 2024, surpassing the initial $100M target. The company maintained 100% partner contract retention across top customers representing over 90% of 2024 revenue, and secured two new revenue agreements.

For 2025, EVH projects revenue between $2.06B-$2.11B (15-18% growth) and Adjusted EBITDA of $135M-$165M. Q1 2025 guidance sets revenue at $440M-$470M with Adjusted EBITDA of $31M-$37M.

Evolent Health (NYSE: EVH) announced significant changes to its Board of Directors. Rick Jelinek, who joined as an independent director in 2023, will become Board Chair at the 2025 Annual Meeting, succeeding Cheryl Scott. Additionally, Brendan Springstubb has been appointed as a new independent director, bringing over 20 years of healthcare investment experience.

The company plans to refresh another independent director seat before the 2025 Annual Meeting through a search process led by the Board's Nominating and Governance Committee. These changes are part of Evolent's ongoing board refreshment efforts, with five new independent directors added in the past three years.

The appointments align with Evolent's commitment to strong corporate governance and shareholder collaboration. Springstubb's addition strengthens the board's capital markets and finance expertise, while Jelinek brings experience as Managing Partner of Czech One Capital Partners and former Executive VP of CVS Health.

Evolent Health (NYSE: EVH) has announced it will release its Q4 2024 financial results on Thursday, February 20, 2025, after market close, followed by a conference call at 5 p.m. ET. Shareholders and analysts can access the live broadcast through Evolent's investor relations website, with analysts able to participate by dialing specific numbers.

The company also announced its executive management team's participation in three upcoming investor conferences in March 2025: the Cowen 45th Annual Health Care Conference in Boston on March 4, the Oppenheimer 35th Annual Health Care MedTech and Services Conference virtually on March 17, and the KeyBanc Annual Health Care Forum virtually on March 19. Audio webcasts will be available on Evolent's investor relations website.

Evolent Health (NYSE: EVH) has announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen, who joined Evolent as Chief Clinical Officer in July 2024, brings experience from Google's population health division, Blue Cross North Carolina, CDC, and CMS. He will succeed Dr. Andrew Hertler, who will transition to a part-time role as senior advisor and CMO emeritus after more than a decade with the company.

Dr. Nguyen's background includes roles in patient care, health policy, and clinical innovation. He previously helped design value-based programs in specialty and primary care at CMS and has worked in clinics serving underserved communities. Dr. Hertler, a medical oncologist with over 40 years of experience, will continue to focus on advancing innovation for Evolent's oncology management solution.

Humana (NYSE: HUM) and Evolent Health (NYSE: EVH) have expanded their strategic medical oncology partnership to streamline prior authorization processes for radiation and surgical oncology services. The collaboration aims to expedite approval requests and improve patient access to care through Evolent's advanced technology platform. Under the expanded partnership, Evolent will serve as Humana's designated utilization management and pathway vendor for radiation and surgical oncology services.

The platform enables providers to access up-to-date therapy choices, submit prior authorization requests in minutes, and receive approvals in seconds, reducing administrative burdens while ensuring CMS compliance.

Evolent Health (EVH) reported Q3 2024 revenue of $621.4 million, up 21.6% year-over-year, with a net loss of $(31.2) million. The company faced challenges with Adjusted EBITDA of $31.8 million, down from $48.7 million in Q3 2023, primarily due to a $42 million increase in medical costs. Despite challenges, EVH announced a record six new contract agreements. The company revised its 2024 outlook and expects Q4 2024 revenue between $642-667 million with Adjusted EBITDA of $22-37 million. Full-year 2024 guidance projects revenue of $2.55-2.575 billion and Adjusted EBITDA of $160-175 million.